On February 9, the Food and Drug Administration approved dostarlimab-gxly, or Jemperli, marketed by GlaxoSmithKline, for adult patients with mismatch repair deficient, or dMMR, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. In April 2021, dostarlimab-gxly received accelerated approval for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen. Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- FDA Oncologic Drugs Advisory Committee to hold a virtual meeting
- GSK, Cytel enter three-year agreement to expand Solara deployment
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
- GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
